Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016

GlobalData, the industry analysis specialist’s new report, “Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global growth hormone deficiency market. The report identifies the key trends shaping and driving the global growth hormone deficiency market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global growth hormone deficiency sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The Scope of the report includes:

• Annualized global growth hormone deficiency revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
• Analysis of the current and future market competition in the global growth hormone deficiency market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with growth hormone deficiency.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global growth hormone deficiency market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global growth hormone deficiency market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global growth hormone deficiency market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of tables
1.2 list of figures

2 GROWTH HORMONE DEFICIENCY (GHD): MARKET CHARACTERIZATION

2.1 Overview
2.2 GHD Drugs Market Size
2.3 GHD Drugs Market Forecast and CAGR
2.4 Drivers and Barriers for the GHD Therapeutics Market
  2.4.1 Drivers for the GHD therapeutics market
  2.4.2 Barriers for the GHD therapeutics market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway

3 GHD THERAPEUTICS MARKET: COMPETITIVE ASSESSMENT

3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Products in the GHD Market
  3.3.1 Genotropin
  3.3.2 Humatrope
  3.3.3 Nutropin
  3.3.4 Saizen
  3.3.5 Norditropin
3.4 Key Takeaway

4 GROWTH HORMONE DEFICIENCY MARKET: PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
  4.2.1 Technology Trends Analytic Framework
4.3 GHD Therapeutics – Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs/Vaccines under Clinical Development
  4.4.1 LB03002 (LG Life Sciences/ Biopartners)
  4.4.2 ALTU-238 (Altus Pharmaceuticals)
  4.4.3 ARX-201 (Ambrx/ Merck Serono)
  4.4.4 NN8630 (Novo Nordisk A/S)
  4.4.5 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen)
4.5 GHD Therapeutics Market – Clinical Pipeline by Mechanism of Action
  4.5.1 GHD Pipeline – Pipeline by Clinical Phases of Development
  4.5.2 GHD Therapeutics – Phase III Clinical Pipeline
  4.5.3 GHD Therapeutics – Phase II Clinical Pipeline
  4.5.4 GHD Therapeutics – Phase I Clinical Pipeline
  4.5.5 GHD Therapeutics – Preclinical Phase Pipeline
4.6 Key Takeaway

5 GHD THERAPEUTICS MARKET: IMPLICATIONS FOR FUTURE MARKET COMPETITION

6 GHD THERAPEUTICS MARKET: FUTURE PLAYERS IN THE GHD MARKET

6.1 Introduction
6.2 LG Life Sciences, Korea
  6.2.1 Overview
  6.2.2 LB03002 (LG Life Sciences/Biopartners)
6.3 Altus Pharmaceuticals, the US
  6.3.1 Overview
  6.3.2 ALTU-238
6.4 Ambrx, Inc., the US
  6.4.1 Overview
  6.4.2 ARX-201
6.5 Novo Nordisk A/S, Denmark
  6.5.1 Overview
  6.5.2 NN8630 (Novo Nordisk A/S)
6.6 Ipsen S.A., France
  6.6.1 Overview
  6.6.2 IGF-I+GH (Insulin-like Growth Factor 1 + Growth Hormone) co-administration (Ipsen)

7 GHD THERAPEUTICS MARKET: APPENDIX

7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
  7.3.1 Coverage
  7.3.2 Secondary Research
  7.3.3 Forecasting
  7.3.4 Primary Research
  7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

LIST OF TABLES

Table 1: GHD Therapeutics, Global, Market Revenues ($bn), 2001-2009
Table 2: GHD Therapeutics, Global, Market Forecast ($bn), 2009-2016
Table 3: GHD Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 4: GHD Therapeutics – Phase III Clinical Pipeline, 2010
Table 5: GHD Therapeutics – Phase II Clinical Pipeline, 2010
Table 6: GHD Therapeutics – Phase I Clinical Pipeline, 2010
Table 7: GHD Therapeutics – Preclinical Phase Pipeline, 2010

LIST OF FIGURES

Figure 1: GHD Therapeutics, Global, Market Revenues ($bn), 2001-2009
Figure 2: GHD Therapeutics, Global, Market Forecast ($bn), 2009-2016
Figure 3: Opportunity and Unmet Need in the GHD Therapeutics Market, 2010
Figure 4: Strategic Competitor Assessment of the Marketed Products for GHD, 2010
Figure 5: Technology Trends Analytic Framework of the GHD Pipeline – 2010
Figure 6: Technology Trends Analytic Framework of the GHD Pipeline – Description, 2010
Figure 7: GHD Therapeutics Market , Clinical Pipeline by Mechanism of Action, 2010
Figure 8: GHD Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the GHD Therapeutics Market, 2010
Figure 10: GHD Therapeutics Market – Clinical Pipeline by Company, Number of Molecules, 2010
Figure 11: GlobalData Methodology
Figure 12: GlobalData Market Forecasting Model

COMPANIES MENTIONED

LG Life Sciences, Korea
Altus Pharmaceuticals, the US
Ambrx, Inc., the US
Novo Nordisk A/S, Denmark
Ipsen S.A., France Skip to top